Orbis Allan Gray Ltd Purchases 162,121 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Orbis Allan Gray Ltd increased its stake in Alnylam Pharmaceuticals by 11.0%, now holding approximately $441.46 million in shares, making up about 2.5% of its total holdings.
• Several firms have upgraded Alnylam Pharmaceuticals' stock ratings, with 22 analysts recommending a "Buy" and a consensus target price of $405.33.
• Alnylam reported a surprising quarterly earnings of $0.32 per share, exceeding estimates and showing a 17.3% year-over-year revenue increase to $773.69 million.

Orbis Allan Gray Ltd increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,634,923 shares of the biopharmaceutical company's stock after buying an additional 162,121 shares during the quarter. Alnylam Pharmaceuticals comprises 2.5% of Orbis Allan Gray Ltd's portfolio, making the stock its 11th largest holding. Orbis Allan Gray Ltd owned about 1.25% of Alnylam Pharmaceuticals worth $441,462,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Investment Management Corp of Ontario boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after acquiring an additional 40 shares in the last quarter. Brevan Howard Capital Management LP boosted its stake in shares of Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Alnylam Pharmaceuticals by 10.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company's stock worth $142,000 after acquiring an additional 49 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 9.2% during the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock worth $161,000 after acquiring an additional 50 shares in the last quarter. Finally, SYM FINANCIAL Corp boosted its stake in shares of Alnylam Pharmaceuticals by 5.3% during the 1st quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company's stock worth $274,000 after acquiring an additional 51 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.1%

NASDAQ ALNY traded up $0.23 during trading on Wednesday, hitting $447.23. 1,270,587 shares of the company traded hands, compared to its average volume of 959,401. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $469.81. The business has a fifty day simple moving average of $379.67 and a 200 day simple moving average of $305.57. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a market capitalization of $58.62 billion, a P/E ratio of -181.06 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same period last year, the company earned ($0.13) earnings per share. The business's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ALNY shares. Barclays increased their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. UBS Group increased their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a report on Friday, August 1st. HC Wainwright restated a "buy" rating and issued a $570.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday. Finally, Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $412.79.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the sale, the chief executive officer directly owned 56,221 shares of the company's stock, valued at $25,483,292.67. This trade represents a 11.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock valued at $25,551,456 in the last ninety days. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.